I-Athena Bioscience, LLC yamemezela izinhlelo zokwethulwa kwezentengiso kwe-Nexiclon XR, okuwukuphela kwamaphilisi e-clonidine akhishwa isikhathi eside kanye ngosuku akhonjiswa ukwelapha umfutho wegazi ophakeme.1 U-Athena uthole amalungelo akhethekile okuthengisa umkhiqizo kwa-Tris Pharma, Inc. ngoFebhuwari 2021. ukwethulwa kuhlelelwe u-Ephreli 2022 kuzo zonke izifundazwe ezingama-50 zase-US.
Ngokwesilinganiso, kuphela i-50% yabantu abadala abanamathela emithini yezifo ezingapheli2, futhi esimweni somfutho wegazi ophezulu (BP), amazinga aphansi okunamathela ahlotshaniswa nokulawulwa kwe-BP okubi kakhulu kanye nemiphumela emibi, okuhlanganisa ukushaywa yisifo, i-myocardial infarction, ukuhluleka kwenhliziyo, kanye ukufa.3-5 I-Nexiclon XR inikeza izinzuzo zomtholampilo ezifanayo ze-antihypertensive ze-clonidine ekhishwa ngokushesha kuthebhulethi elula, kanye ngosuku.6
"Sikholelwa ukuthi ukusizakala kwethebhulethi esetshenziswa kanye ngosuku kungaba nomthelela ekwandiseni ukunamathela kwesiguli ezinhlotsheni zemithi," kusho uJeff Bryant, i-CEO yakwa-Athena. "Ukuthobela okungcono kufanele kunikeze imiphumela yokwelapha ethuthukisiwe kulabo abaphethwe yi-hypertension."
"Ukwethulwa kwe-Nexiclon XR kukhombisa impumelelo eqhubekayo ye-Tris ekuletheni imithi ehlukene esekelwe kubuchwepheshe emakethe," kusho i-CEO yakwa-Tris u-Ketan Mehta. "Uma sibheka irekhodi labo eliqinisekisiwe, siyajabula ukuthi u-Athena unguzakwethu, wethula lo mkhiqizo obalulekile wenhliziyo." I-Nexiclon isuselwe kubuchwepheshe bokulethwa kwezidakamizwa be-Tris's LiquiXR®, obuholele ekuthuthukisweni kwemikhiqizo eminingi yesigaba sokuqala.
LOKHO ONGAKUTHATHE KULESI SIHLOKO:
- On average, only 50% of adults adhere to chronic disease medications2, and in the case of high blood pressure (BP), lower levels of adherence are associated with worse BP control and adverse outcomes, including stroke, myocardial infarction, heart failure, and death.
- “We believe the convenience of a once-daily tablet can contribute to increased patient adherence to medication regimens,”.
- The launch is set for April 2022 in all 50 U.
